(NASDAQ: IBIO) Ibio's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 16.65%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 33.72%.
Ibio's earnings in 2026 is -$27,606,000.On average, 7 Wall Street analysts forecast IBIO's earnings for 2027 to be -$14,675,047, with the lowest IBIO earnings forecast at -$18,987,146, and the highest IBIO earnings forecast at -$9,806,548. On average, 9 Wall Street analysts forecast IBIO's earnings for 2027 to be -$15,673,586, with the lowest IBIO earnings forecast at -$21,421,396, and the highest IBIO earnings forecast at -$11,475,748.
In 2028, IBIO is forecast to generate -$25,490,070 in earnings, with the lowest earnings forecast at -$40,895,391 and the highest earnings forecast at -$15,127,122.